Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.7103
-0.0028 (-0.39%)
Nov 19, 2025, 1:21 PM EST - Market open
Barinthus Biotherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Barinthus Biotherapeutics stock has a target of 4.00, which predicts a 463.14% increase from the current stock price of 0.71.
Price Target: $4.00 (+463.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Barinthus Biotherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +463.14% | Nov 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +322.36% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +322.36% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +603.93% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +603.93% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
n/a
from 14.97M
Revenue Next Year
n/a
EPS This Year
-1.90
from -1.55
EPS Next Year
-1.46
from -1.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.95 | -1.50 | |
| Avg | -1.90 | -1.46 | |
| Low | -1.82 | -1.40 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.